Quartz·1 min read·medium
Moderna beat earnings expectations but its norovirus vaccine trial hit a wall
✦AI Summary
Moderna reported financial results that exceeded Wall Street's loss expectations for the quarter. However, the company's stock price fell following news that its norovirus vaccine candidate failed to meet a primary goal in a recent clinical trial.
The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in